Recursion Pharmaceuticals (RXRX) Assets Average (2021 - 2026)

Recursion Pharmaceuticals (RXRX) has 6 years of Assets Average data on file, last reported at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 2.17% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 2.17% YoY), and the FY2025 full-year result was $1.5 billion, up 39.03% from the prior year.
• Assets Average for Q1 2026 stood at $1.4 billion, down from $1.4 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.4 billion in Q4 2025 and bottomed at $605.8 million in Q1 2024.
• The 5-year median for Assets Average is $672.3 million (2022), against an average of $897.8 million.
• The widest annual swing landed in 2022, when Assets Average surged 135.69%; it then slipped 8.81% in 2024.
• A 5-year view of Assets Average shows it stood at $656.4 million in 2022, then dropped by 2.16% to $642.3 million in 2023, then jumped by 69.33% to $1.1 billion in 2024, then surged by 32.12% to $1.4 billion in 2025, then declined by 2.09% to $1.4 billion in 2026.
• The last three Assets Average figures came in at $1.4 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.

Peer Comparison